Achieve Life Sciences, Inc. (ACHV) Income Statement
ACHV 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsACHV revenue and net income
ACHV profit margins
ACHV growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ACHV quarterly EPS vs estimates
Achieve Life Sciences beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 5, 2026 (estimate $-0.20).
ACHV income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $5.1M |
| Cost of revenue | $228,000 | $229,000 | $228,000 | $236,000 | $250,000 | $255,000 | $254,000 | $282,000 | $282,000 | $0 |
| Gross profit | −$228,000 | −$229,000 | −$228,000 | −$236,000 | −$250,000 | −$255,000 | −$254,000 | −$282,000 | −$282,000 | $5.1M |
| Research & development | $23.0M | $22.8M | $15.8M | $30.1M | $24.0M | $6.9M | $9.7M | $5.9M | $3.1M | $14.8M |
| Sales, general & admin | $31.9M | $16.3M | $11.4M | $10.7M | $9.1M | $7.9M | $6.9M | $6.9M | $3.5M | $8.9M |
| Total operating expenses | $54.7M | $38.8M | $27.2M | $40.8M | $33.1M | $14.5M | $16.5M | $12.8M | $6.6M | $23.7M |
| Operating income | −$54.9M | −$39.1M | −$27.2M | −$40.8M | −$33.1M | −$14.8M | −$16.5M | −$12.8M | −$6.6M | −$21.2M |
| Interest income | $1.5M | $2.4M | $735,000 | $199,000 | $17,000 | $69,000 | $170,000 | $171,000 | $21,000 | $203,000 |
| Interest expense | $819,000 | $2.2M | $2.9M | $1.8M | $17,000 | $69,000 | $0 | $0 | $0 | $0 |
| Income before taxes | −$54.6M | −$39.8M | −$29.8M | −$42.4M | −$33.2M | −$14.7M | −$16.4M | −$12.7M | −$13.6M | −$20.1M |
| Income taxes | — | −$39.8M | — | −$475,000 | −$250,000 | −$69,000 | −$254,000 | −$126,000 | −$3.1M | −$1.1M |
| Net income | −$54.6M | −$39.8M | −$29.8M | −$41.9M | −$32.9M | −$14.7M | −$16.1M | −$12.7M | −$10.6M | −$20.1M |
| EBITDA | −$53.6M | −$37.4M | −$26.7M | −$40.6M | −$32.8M | −$14.5M | −$16.3M | −$12.5M | −$13.4M | −$19.9M |
| EPS (diluted) | −$1.30 | −$1.23 | −$1.53 | −$4.06 | −$4.30 | −$6.13 | −$42.60 | −$39.03 | −$184.03 | −$1540.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | 100.0% |
| Operating margin | — | — | — | — | — | — | — | — | — | −418.6% |
| Net margin | — | — | — | — | — | — | — | — | — | −397.6% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $228,000 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $57,000 | $57,000 | $54,000 | $55,000 | $62,000 | $114,000 | $57,000 | $57,000 | $57,000 | $57,000 | $100,000 |
| Gross profit | — | −$57,000 | −$57,000 | −$54,000 | −$55,000 | −$62,000 | $114,000 | −$57,000 | −$57,000 | −$57,000 | −$57,000 | −$100,000 |
| Research & development | $3.8M | $3.3M | $3.9M | $5.3M | $6.7M | $7.1M | $7.3M | $7.6M | $5.1M | $2.8M | $2.1M | $3.6M |
| Sales, general & admin | $14.6M | $7.1M | $10.9M | $9.4M | $5.9M | $5.8M | $4.9M | $4.9M | $3.3M | $3.2M | $2.3M | $3.0M |
| Total operating expenses | $18.4M | $10.4M | $14.7M | $14.6M | $12.6M | $12.9M | $12.2M | $12.5M | $8.4M | $6.0M | $4.4M | $6.5M |
| Operating income | −$18.4M | −$10.5M | −$14.7M | −$14.7M | −$12.6M | −$12.9M | −$12.2M | −$12.5M | −$8.4M | −$6.0M | −$4.4M | −$6.6M |
| Interest income | $1.5M | $297,000 | $427,000 | $554,000 | $192,000 | $322,000 | $482,000 | $673,000 | $833,000 | $368,000 | $208,000 | $262,000 |
| Interest expense | $277,000 | $274,000 | $251,000 | $192,000 | $191,000 | $185,000 | $197,000 | $366,000 | $804,000 | $813,000 | $787,000 | $781,000 |
| Income before taxes | −$74.8M | −$10.2M | −$14.7M | −$14.4M | −$12.7M | −$12.8M | −$12.4M | −$12.5M | −$8.5M | −$6.5M | −$5.5M | −$7.1M |
| Income taxes | — | — | — | — | — | — | — | — | −$87,000 | $13,724 | $13,188 | $461,000 |
| Net income | −$74.8M | −$10.2M | −$14.7M | −$14.4M | −$12.7M | −$12.8M | −$12.4M | −$12.5M | −$8.5M | −$6.5M | −$5.5M | −$7.1M |
| EBITDA | −$74.4M | −$9.8M | −$14.4M | −$14.2M | −$12.5M | −$12.6M | −$12.1M | −$12.1M | −$7.6M | −$5.6M | −$4.6M | −$6.3M |
| EPS (diluted) | −$0.28 | −$0.19 | −$0.28 | −$0.28 | −$0.37 | −$0.37 | −$0.36 | −$0.36 | −$0.25 | −$0.26 | −$0.26 | −$0.34 |
| Gross margin | — | — | — | — | — | — | 50.0% | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | −5,346.5% | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | −5,421.1% | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ACHV's financial statements (latest annual report filed March 24, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ACHV financial results
Achieve Life Sciences reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $54.6 million. Diluted earnings per share came to −$1.30.
See the ACHV stock overview for the latest quote and news, or the ACHV chart for price history and technical indicators.
ACHV income statement FAQ
Does Achieve Life Sciences have revenue?
Achieve Life Sciences reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Achieve Life Sciences profitable?
No. Achieve Life Sciences reported a net loss of $54.6 million in fiscal 2025.
How much does Achieve Life Sciences spend on research and development?
Achieve Life Sciences spent $23.0 million on research and development in fiscal 2025.
What are Achieve Life Sciences's earnings per share?
Achieve Life Sciences earned $-1.30 per diluted share in fiscal 2025, compared with $-1.23 a year earlier.
When will Achieve Life Sciences report its next earnings?
Achieve Life Sciences is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens.
When does Achieve Life Sciences's fiscal year end?
Achieve Life Sciences's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 24, 2026.